US4915932A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Macroaggregates for radiation synovectomy
Assignee: Australian Nuclear Science and Technology Organisation
•
Filing: 1988-10-13
•
Granted: 1990-04-10
•
Expires: 2008-10-13
Abstract
Abstract A formulation is provided for the treatment of synovial inflammation, the formulation consisting of dysprosium-165 hydroxide macroaggregates or yttrium-90 hydroxide macroaggregates, wherein the formulation is substantially devoid of other co-precipitating agents in particular, ferric hydroxide. A method of treatment of synovial inflammation is also provided in which the method comprises adminstering an intra-articular injection of the above formulation. Preferably the above formulation is in the form of a isotonic apyrogenic injectable solution.
Inventors
- 👤 Ashley B. McLaren
- 👤 Eric L. Hetherington
- 👤 Desmond J. Maddalena
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 09:03
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/12; A61K51/1217; A61K51/1241; A61K51/1255; A61K2121/00
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
35 words
A formulation for treatment of synovial inflammation consisting of an active ingredient selected from the group consisting of dysprosium-165 hydroxide macroaggregates and yttrium-90 hydroxide macroaggregates, as the only ingredient suspended in a pharmaceutically acceptable carrier.
Claim 2
Dependent Claim
35 words
A formulation for treatment of synovial inflammation consisting of an active ingredient selected from the group consisting of dysprosium-165 hydroxide macroaggregates and yttrium-90 hydroxide macroaggregates, as the only ingredient suspended in a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
40 words
A formulation for treatment of synovial inflammation, consisting of an active ingredient selected from the group comprising dysprosium-165 hydroxide macroaggregates and yttrium-90 hydroxide macroaggregates, suspended in a pharmaceutically acceptable carrier, wherein the formulation is substantially devoid of other co-precititating agents.
Claim 4
Dependent Claim
40 words
A formulation for treatment of synovial inflammation, consisting of an active ingredient selected from the group comprising dysprosium-165 hydroxide macroaggregates and yttrium-90 hydroxide macroaggregates, suspended in a pharmaceutically acceptable carrier, wherein the formulation is substantially devoid of other co-precititating agents.
Claim 5
Dependent Claim
37 words
A formulation for treatment of synovial inflammation, consisting of an active ingredient selected from the group comprising dysprosium-165 hydroxide macroaggregates and yttrium-90 hydroxide macroaggregates, suspended in a pharmaceutically acceptable carrier, in which there is no ferric hydroxide.
Claim 6
Dependent Claim
37 words
A formulation for treatment of synovial inflammation, consisting of an active ingredient selected from the group comprising dysprosium-165 hydroxide macroaggregates and yttrium-90 hydroxide macroaggregates, suspended in a pharmaceutically acceptable carrier, in which there is no ferric hydroxide.
Claim 7
Dependent Claim
20 words
A formulation according to claim 1 in which the formulation is in the form of an isotonic apyrogenic injectable solution.
Claim 8
Dependent Claim
20 words
A formulation according to claim 2 in which the formulation is in the form of an isotonic apyrogenic injectable solution.
Claim 9
Dependent Claim
20 words
A formulation according to claim 3 in which the formulation is in the form of an isotonic apyrogenic injectable solution.
Claim 10
Independent Claim
53 words
A method of treatment of synovial inflammation in human subjects, which method comprises administering to said subject an intra-articular injection of an effective amount formulation consisting of an active ingredient selected from the group consisting of dysprosium-165 hydroxide macroaggregates and yttrium-90 hydroxide macroaggregates, as the only ingredient suspended in a pharmaceutically acceptable carrier.
Claim 11
Independent Claim
53 words
A method of treatment of synovial inflammation in human subjects, which method comprises administering to said subject an intra-articular injection of an effective amount formulation consisting of an active ingredient selected from the group consisting of dysprosium-165 hydroxide macroaggregates and yttrium-90 hydroxide macroaggregates, as the only ingredient suspended in a pharmaceutically acceptable carrier.
Claim 12
Independent Claim
60 words
A method of treatment of synovial inflammation in human subjects, which method comprises administering to said subject an intra-articular injection of an effective amount a formulation consisting of an active ingredient selected from the group consisting of dysprosium-165 hydroxide macroaggregates and yttrium-90 hydroxide macroaggregates, suspended in a pharmaceutically acceptable carrier, wherein the formulation is substantially devoid of other co-precipitating agents.
Claim 13
Independent Claim
60 words
A method of treatment of synovial inflammation in human subjects, which method comprises administering to said subject an intra-articular injection of an effective amount a formulation consisting of an active ingredient selected from the group consisting of dysprosium-165 hydroxide macroaggregates and yttrium-90 hydroxide macroaggregates, suspended in a pharmaceutically acceptable carrier, wherein the formulation is substantially devoid of other co-precipitating agents.
Claim 14
Independent Claim
56 words
A method of treatment of synovial inflammation in human subjects, which method comprises administering to said subject an intra-articular injection of an effective amount formulation consisting of an active ingredient selected from the group consisting of dysprosium-165 hydroxide macroaggregates and yttrium-90 hydroxide macroaggregates, suspended in a pharmaceutically acceptable carrier, in which there is no ferric hydroxide.
Claim 15
Independent Claim
56 words
A method of treatment of synovial inflammation in human subjects, which method comprises administering to said subject an intra-articular injection of an effective amount formulation consisting of an active ingredient selected from the group consisting of dysprosium-165 hydroxide macroaggregates and yttrium-90 hydroxide macroaggregates, suspended in a pharmaceutically acceptable carrier, in which there is no ferric hydroxide.
Claim 16
Dependent Claim
19 words
A method according to claim 7 in which the carrier for the above formulation is an isotonic saline solution.
Claim 17
Dependent Claim
19 words
A method according to claim 8 in which the carrier for the above formulation is an isotonic saline solution.
Claim 18
Dependent Claim
19 words
A method according to claim 9 in which the carrier for the above formulation is an isotonic saline solution.
References Cited (Backward Citations)
US4752464A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-04-09 | 1993-10-09 | 1994-04-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-04-09 | 1997-10-09 | 1998-04-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-04-09 | 2001-10-09 | 2002-04-10 | $7700.00 | Window Closed / Lapsed |